#USA #Glenmark Pharmaceuticals #Elmwood Park #Sodium Bicarbonate #Abbott Pharmaceuticals

Glenmark Pharmaceuticals Preparing for the Launch of 8.4% Sodium Bicarbonate Injection USP

Glenmark Pharmaceuticals Inc., USA, has exciting news for the healthcare sector as it prepares to launch its 8.4% Sodium Bicarbonate Injection USP in convenient single-dose vials. This product, delivering 50 mEq/50 mL at a concentration of 1 mEq/mL, will be available starting in November 2025. This announcement demonstrates Glenmark's commitment to expanding its injectable product portfolio while also ensuring quality and affordability for patients in need.

The 8.4% Sodium Bicarbonate Injection USP is bioequivalent and therapeutically equivalent to the well-established product from Abbott Laboratories, allowing healthcare providers to have reliable alternatives for their patients. According to sales data from IQVIA® for the year ending August 2025, the market for 8.4% Sodium Bicarbonate Injection, which includes both the brand and other therapeutically equivalent products, reached annual sales of approximately $63.8 million, indicating a significant demand within the medical field.

Marc Kikuchi, President and Business Head of North America at Glenmark, expressed the company’s enthusiasm about the new product launch: “We are pleased to announce the expansion of our injectable portfolio…which further reinforces our dedication to bringing quality and affordable alternatives to market to patients in need.” Glenmark aims not only to fulfil healthcare needs with effective solutions but also to adhere to the highest standards of manufacturing practices, evident from their manufacturing facilities located across four continents and operations in over 80 countries.

Glenmark Pharmaceuticals has established itself as a prominent player in the pharmaceutical industry, engaging in both consumable products and research-driven initiatives. The company has been recognized in the past for making positive impacts within local communities, influencing over 3 million lives through various corporate social responsibility (CSR) interventions over the last decade. Their commitment to sustainability is further reflected in their recent approval from the Science Based Target initiative (SBTi) for their greenhouse gas emission reduction goals.

As the healthcare landscape continues to evolve, Glenmark's new Sodium Bicarbonate Injection aims to provide healthcare professionals with an essential medication that is vital for various clinical applications. This product's release is anticipated to contribute significantly to the therapeutic options available for patient care, especially in emergency settings who require sodium bicarbonate for metabolic acidosis, bicarbonate loss, and other conditions. Specifically, it serves as an important option in treating cesarean deliveries and cardiac arrest scenarios.

The anticipation for the availability of this injection builds upon Glenmark’s previous successes in the pharmaceutical market, ultimately reinforcing the company's mission to provide high-quality medications. As healthcare providers await the November launch, Glenmark is carefully preparing its marketing strategy to ensure a smooth rollout.

In addition, healthcare providers are encouraged to stay up-to-date with Glenmark’s announcements and product availability through their website and professional social media channels; this enables health professionals to better serve their patients while having access to necessary information regarding Glenmark’s products including their innovative offerings.

About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals, listed on BSE under number 532296, and NSE under GLENMARK, continues to lead the way with a mixed portfolio of branded, generic, and OTC pharmaceutical products. Focusing primarily on therapeutic areas like respiratory, dermatology, and oncology, the company not only strives for market growth but also prioritizes ethical practices and sustainability. Their continuous research and development initiatives solidify Glenmark's position as a globally competitive player, fostering a robust pipeline of pharmaceutical innovations catering to diverse markets.

Stay tuned for the launch of the 8.4% Sodium Bicarbonate Injection USP that promises to enhance patient care by providing healthcare professionals with an additional, reliable resource for critical medical needs.